Enterprise Value
2.178B
Cash
174M
Avg Qtr Burn
N/A
Short % of Float
10.25%
Insider Ownership
1.11%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZILRETTA® (triamcinolone acetonide) Details Osteoarthritis Knee Pain | Approved Quarterly sales | |
Exparel (bupivacaine liposome) Details Post operative acute pain | Approved Quarterly sales | |
Exparel (bupivacaine liposome) Details Post operative acute pain | PDUFA Approval decision | |
PCRX-201 (FX201) (humantakinogene hadenovec) Details Osteoarthritis pain | Phase 1 Update | |
PCRX-301 (FX301) (NaV1.7 inhibitor) Details Post operative acute pain , Pain | Failed Discontinued |